Honeybee venom therapy and viral infection: a systematic synthesis of venom antiviral activity
Authors:
Open Access
- 27 February 2026
- journal article
- review article
- Published by Frontiers Media SA in Frontiers: A Journal of Women Studies
- Vol. 6, 1751614
Abstract
The bioactive components of honeybee venom (HBV) have displayed broad evolutionary antiviral activity in animal models; however, there is limited evidence for the efficacy, indications, or side effects of the use of HBV in humans. We performed a systematic review and meta-analysis of the available preclinical and clinical evidence systematically assessing the antiviral efficacy and safety of HBV. A comprehensive search strategy for all studies reporting HBV in relation to direct-acting antiviral effects was performed through electronic databases from their inception up to October 2025. A total of 32 articles were identified for quantitative synthesis, with some included under meta-analysis. Although majority of the studies show high heterogeneity and limitations, the meta-analysis results provide encouraging evidence for the broad-spectrum antiviral property of HBV against numerous viruses, such as influenza viruses, herpes simplex virus, HIV, hepatitis viruses, and emerging coronaviruses. Mechanistically, the HBV components directly disrupt viral replication or do so via body immunomodulation pathways. The main adverse effects of HBV include dose-related cytotoxicity and mild allergic responses, with rare instances (less than 0.1%) of anaphylaxis. Overall, the antiviral roles of HBV are strongly supported in preclinical studies, although the clinical data on humans have limitations. Therefore, improving formulations and conducting safety assessment in future clinical practice, particularly through the use of nanocarriers or combined therapeutic strategies, may enhance the imperative HBV antiviral potency and reduce its limitations.Keywords
This publication has 16 references indexed in Scilit:
- Harnessing the power of bee venom for therapeutic and regenerative medical applications: an updated reviewFrontiers in Pharmacology, 2024
- Antiviral Attributes of Bee Venom as a Possible Therapeutic Approach Against SARS-CoV-2 InfectionFuture Virology, 2023
- Fighting against the second wave of COVID-19: Can honeybee products help protect against the pandemic?Saudi Journal of Biological Sciences, 2021
- Therapeutic options for the 2019 novel coronavirus (2019-nCoV)Nature Reviews Drug Discovery, 2020
- Melittin: a venom-derived peptide with promising anti-viral propertiesEuropean Journal of Clinical Microbiology & Infectious Diseases, 2019
- Potencial antiviral e virucida da melitina e apamina contra herpesvírus bovino tipo 1 e vírus da diarreia viral bovinaPesquisa Veterinária Brasileira, 2018
- Risk Associated with Bee Venom Therapy: A Systematic Review and Meta-AnalysisPLOS ONE, 2015
- Melittin-loaded immunoliposomes against viral surface proteins, a new approach to antiviral therapyAntiviral Research, 2013
- Bee venom modulates murine Th1/Th2 lineage developmentInternational Immunopharmacology, 2005
- Two species of full-length cDNA are synthesized in high yield by melittin-treated avian retrovirus particles.Proceedings of the National Academy of Sciences, 1980